You just read:

CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis

News provided by

Regeneron Pharmaceuticals, Inc.

Sep 20, 2019, 06:44 ET